UiPath Inc. (NYSE:PATH) Receives Consensus Rating of “Hold” from Brokerages

UiPath Inc. (NYSE:PATH) has been assigned an average recommendation of “Hold” from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. Sixteen equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $17.47.

PATH has been the topic of a number of recent analyst reports. DA Davidson raised their target price on shares of UiPath from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. BMO Capital Markets lifted their price objective on shares of UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a report on Friday, September 6th. Evercore ISI upped their target price on shares of UiPath from $13.00 to $16.00 and gave the stock an “in-line” rating in a research report on Friday, September 6th. TD Cowen dropped their price target on UiPath from $17.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Finally, Wells Fargo & Company reduced their price objective on UiPath from $15.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd.

UiPath Price Performance

PATH opened at $12.57 on Friday. The firm has a market capitalization of $6.91 billion, a P/E ratio of -62.85 and a beta of 0.88. UiPath has a one year low of $10.37 and a one year high of $27.87. The company has a fifty day moving average price of $12.54 and a 200-day moving average price of $13.86.

UiPath (NYSE:PATH) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The business had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. During the same period in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. On average, analysts expect that UiPath will post -0.23 earnings per share for the current year.

Insider Buying and Selling at UiPath

In related news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $12.07, for a total value of $575,388.97. Following the sale, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at $10,258,498.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.37% of the stock is currently owned by corporate insiders.

Institutional Trading of UiPath

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cowa LLC increased its position in UiPath by 4.4% during the 3rd quarter. Cowa LLC now owns 26,681 shares of the healthcare company’s stock valued at $342,000 after purchasing an additional 1,118 shares during the period. Capital Performance Advisors LLP bought a new stake in shares of UiPath during the 3rd quarter valued at about $65,000. Principal Financial Group Inc. increased its position in shares of UiPath by 10.5% during the third quarter. Principal Financial Group Inc. now owns 36,685 shares of the healthcare company’s stock valued at $470,000 after buying an additional 3,477 shares during the period. Amalgamated Bank raised its stake in UiPath by 7.1% in the third quarter. Amalgamated Bank now owns 27,312 shares of the healthcare company’s stock worth $350,000 after buying an additional 1,811 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in UiPath by 17.7% in the third quarter. Janney Montgomery Scott LLC now owns 104,608 shares of the healthcare company’s stock worth $1,339,000 after buying an additional 15,698 shares during the period. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.